Background: Antimicrobial stewardship is required to ensure the appropriate use of antimicrobials. However, few reports have shown the impact of antimicrobial stewardship on clinical outcomes.
| INTRODUC TI ON
Carbapenems have traditionally been recommended as first-line agents for the treatment of documented or suspected drug-resistant organism Gram negative infection. 1 In patients receiving empirical broad-spectrum antimicrobial therapy, antimicrobials should be deescalated based on the culture results and susceptibility.
Guidelines by the Infectious Diseases Society of America (IDSA)
advocate antimicrobial pre-authorisation as an effective method for reducing the excursive use of broad-spectrum antibiotics. 2 Previous reports have shown that the implementation of carbapenem restriction reduces the incidence of carbapenem-resistant bacteria such as
Pseudomonas aeruginosa in association with a decrease in carbapenem use. [3] [4] [5] However, there are several problems with implementing a pre-authorisation intervention, including differences in the skills of healthcare professionals and the difficulty of establishing a 24-hour approval system. Moreover, pre-authorisation is a strategy to improve antibiotic use before they are prescribed. Therefore, the recommendation of de-escalation or discontinuation of broadspectrum antibiotics, which is intervention after initiation of antimicrobials, is complicated by the restriction strategy.
The IDSA guideline also recommends a prospective audit with intervention and feedback strategy as a core component of any stewardship programme. 2 This strategy can be used to recommend de-escalation and discontinuation of broad-spectrum antimicrobials. Horikoshi et al reported that implementing antimicrobial preauthorisation and prospective audit with intervention and feedback for carbapenem reduces the infection-related mortality. 6 However, to our knowledge, there has been no report showing the clinical impact of a prospective audit with intervention and feedback without carbapenem restriction. In August 2009, we developed a hospitalwide, multidisciplinary intervention programme based on this prospective audit with an intervention and feedback strategy without carbapenem restriction to optimise antibiotic use within 24 hours after the onset of therapy. This strategy was unique in that it targeted all patients who received intravenous antimicrobials. We found that the programme was highly effective in decreasing carbapenem consumption and drug-resistant bacteria, without carbapenem restriction. 7 However, it remains uncertain whether our extensive intervention leads to improved rates of clinical failure, mortality, and re-infection.
The aim of the present study was to evaluate the impact of the appropriate use of antimicrobials by implementing a prospective audit with intervention and feedback without carbapenem restriction on the clinical outcomes in patients receiving carbapenem injection.
| MATERIAL S AND ME THODS

| Study design
A single-centre, prospective cohort study was conducted at Gifu University Hospital, which has 614 beds and provides tertiary 
| Intervention
For antimicrobial intervention, the antimicrobial stewardship team (AST) performed daily reviews of prescriptions for inpatients receiving intravenous antimicrobials according to the prospective audit with intervention and feedback strategy, as mentioned in our previous report. 7 Briefly, the AST comprised physicians and pharmacist with specialty in infectious diseases, and the members of AST were in charge of the daily review of prescriptions for all intravenous antimicrobials within 24 hours after initiation of the therapy for every hospitalised patient. The physician and pharmacist conducted real-time interventions for patients who were prescribed with inappropriate antimicrobials by telephone. The appropriateness of antimicrobial use was decided according to published guidelines, mainly the Sanford guide to antimicrobial therapy. 9 Intervention for antimicrobial choice or duration was mainly performed by the physician, while intervention for dose adjustment was performed by the pharmacist. appropriate treatment duration. In the extended intervention period, inpatients receiving intravenous antimicrobials were reviewed at least twice weekly to enhance the appropriate use of antimicrobials.
| Outcomes
The primary outcome was defined as clinical failure and the secondary outcomes were re-infection and adverse events. The number
What's known
• The IDSA guideline advocates antimicrobial pre-authorisation and a prospective audit with intervention and feedback strategy as core components of any stewardship program.
• Effectiveness of combination of both strategies is known, but the impact of a prospective audit with intervention and feedback without carbapenem restriction on the clinical outcomes is unclear.
What's new
• A prospective audit with intervention and feedback strategy without carbapenem restriction significantly facilitated the choice of optimal antimicrobials.
• The 30-d re-infection rate was defined as infection caused by the same strain of bacteria with the same antibiotic susceptibility that occurred at the same infection site within 30 days after antimicrobial therapy was discontinued. 
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TA B L E 1 Comparison of the demographics of patients between the intervention group and non-intervention group
| Adverse events
Adverse events associated with antimicrobial agents were graded according to the Japan Clinical Oncology Group/Japan Society of Clinical Oncology's version 3.0 described in the Japanese Society of Chemotherapy's criteria for assessing adverse reactions and abnormal laboratory values associated with antibacterial agents. 13 Incidence rates of grade 2 and higher adverse events were compared between the intervention and non-intervention groups.
| Statistical analyses
Data were analysed by using SPSS version 21 (SPPS Inc., Chicago, IL, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego, CA, USA). Parametric analysis was performed using t-test, while non-parametric analysis was conducted using MannWhitney U-test or chi-squared test. Clinical failure and 30-d reinfection were analysed using the Kaplan-Meier method, and the curves were statistically compared using the Mantel-Cox longrank test to determine the hazard ratios (HRs) and 95% confidence intervals (CIs). Univariate and multivariate Cox proportional hazard analyses were performed to assess the potential prognostic factors of infectious diseases. Variables for 30-d clinical failure that were different (P < 0.10) between patients with and without clinical failure were subjected to univariate and multivariate Cox proportional hazard analyses. Statistically significant differences were defined by P < 0.05.
| Ethical approval
This study was conducted in accordance with the guidelines for human studies of the Ethics Committee of Gifu University Graduate 
| Intervention
We observed 18 cases of intervention and 26 cases of consultation for carbapenems during 6-month intervention period and acceptance rate was approximately 100%. The most frequent intervention was antimicrobial selection (22 cases), followed in order by dose adjustment (16 cases).
| Appropriate use of antimicrobials
The most frequently used carbapenem was meropenem in both groups (Table 2 ). No significant difference in the used carbapenems was noted between the two groups, except for doripenem (15.3% for the nonintervention group vs 36.4% for the intervention group, P = 0.003) and biapenem (8.5% vs 5.2%, P < 0.001). The rate of carbapenems monotherapy was significantly lower in the intervention group (98.4% vs 94.6%, P = 0.002). The used antimicrobials in the combination therapy were quinolones (1.2%) and macrolides (0.4%) in the non-intervention group, while those were anti-methicillin-resistant Staphylococcus aureus agents (2.3%), macrolides (1.7%), quinolones (0.6%), and others (1.7%) in the intervention group. No significant differences were noted in the used antimicrobials in the combination therapy between the two groups. The antimicrobial intervention significantly increased the rate of obtaining bacterial culture (82.7% vs 96.0%, P < 0.001; Table 2 ). The rate of choice of effective antimicrobials on day 2 from the onset of infection was significantly higher in the intervention group (63.2% vs 90.2%, P < 0.001).
Kaplan-Meier plots indicated that the rate of effective antimicrobial selection was significantly higher in the intervention group than in the nonintervention group (HR, 2.00; 95% CI, 1.36-2.64; P < 0.001; Figure 1 ).
The rate of de-escalation based on the culture results was also significantly elevated after intervention (26.5% vs 82.8%, P < 0.001; Table 2 ).
| Clinical outcomes
The antimicrobial intervention arm had significantly lower rate of clinical failure (42.3% vs 28.3%, P = 0.003; Table 2 ). Kaplan-Meier Figure 2A ). The rate of 30-d re-infection was significantly lower (13.4% vs 3.2%, P < 0.001; Table 2 ), and the re-infection-free survival was significantly longer in the intervention group (HR, 0.35; 95% CI, 0.18-0.68; P = 0.002; Figure 2B ). No significant differences were noted in the treatment duration (7 [5] [6] [7] [8] [9] [10] between the non-intervention and intervention groups.
| Incidence of adverse events associated with carbapenems
The incidence of hepatotoxicity (grade ≥ 2), in particular, elevation of aspartate aminotransferase or alanine aminotransferase, was markedly lower in the intervention group (19.4% vs 3.5%, P < 0.001; Table 2 ). In addition, the overall incidence of adverse events was also significantly lower in the intervention group than in the non-intervention group (24.2% vs 5.2%, P < 0.001; Table 2 ), although hepatotoxicity was still the most common adverse event (grade ≥ 2) in both groups. 
TA B L E 3 Comparison of the demographics of patients with and without clinical failure
| Risk factors for clinical failure
The demographics of patients with and without clinical failure are shown in Table 3 As shown in Table 4 
| D ISCUSS I ON
Several reports have shown that restricting carbapenem use reduces both carbapenem consumption and the incidence of carbapenem resistant bacteria. 4, 14 However, the recommendation of de-escalation or discontinuation of broad-spectrum antibiotics is complicated by the restriction strategy. Implementation of a prospective audit with intervention and feedback is useful for solving these problems.
Reports have shown that implementing a pre-authorisation and prospective audit with intervention and feedback reduces the infectionrelated mortality rate 6 and treatment duration, 15 and improves the clinical response 16 in patients receiving carbapenem. However, it is still unclear whether or not a prospective audit with intervention and feedback without carbapenem restriction improves clinical outcomes in patients receiving carbapenem injection.
In the present study, we evaluated the clinical outcomes of our prospective audit with intervention and feedback strategy without carbapenem restriction in patients receiving carbapenem injection.
We report for the first time that implementing antimicrobial stew- with the present result. Implementation of a daily review of antimicrobial prescriptions within 24 hours after initiation of antibiotic therapy facilitated the optimal choice of antimicrobials. Indeed, the rate of choice of effective antimicrobials on day2 from the onset of infection increased significantly after intervention. Furthermore, the rate of de-escalation was also markedly elevated in the intervention group. In addition, we performed an intervention for treatment duration according to the causative microorganism and infection source, which was complicated by the restriction strategy. According to these results, both the rates of clinical failure and re-infection were significantly reduced in patients receiving carbapenem injection after undergoing prospective audit with intervention and feedback.
In contrast, implementing antimicrobial intervention markedly reduced the incidence of adverse events. In particular, the rate of the incidence of hepatotoxicity (grade ≥ 2) was significantly reduced, although carbapenems were not changed to another agent in some cases of moderate grade hepatotoxicity. The mechanism of carbapenems associated hepatotoxicity is unclear. However, Imani et al reported that that hepatotoxicity was not related to the trough concentration of β-lactam antibiotics, including carbapenems. 17 The trough concentration of carbapenems is known to be elevated in subjects with decreased renal function, 18 resulting in the need for dose adjustment. Therefore, we speculate that carbapenem associated hepatotoxicity is not related to the dose of carbapenems. Further, approximately 80% of our interventions for dose adjustment were dose elevation, as shown in our previous report. 7 Moreover, we did not perform any interventions for preventing adverse events. The available data suggest that facilitation of de-escalation as soon as culture results are obtained and susceptibility is determined, for example, changing to cephalosporins, which are associated with low incidence of hepatotoxicity with narrow spectrum, effectively reduced the onset of hepatotoxicity.
A multivariate Cox proportional hazard analysis indicated that non-implementation of antimicrobial stewardship was a significant risk factor for clinical failure. Respiratory infection was also a significant risk factor for clinical failure. Community-acquired pneumonia, together with influenza, is the eighth leading cause of death in the United States. 19 Therefore, the adverse prognostic characteristics of respiratory infection suggest that it will become a significant risk factor for clinical failure. In contrast, urinary tract infection was a protective factor for clinical failure. This may be explained by the fact that carbapenem has high penetration into the urinary tract.
There are several limitations of the present study. First, we conducted a nonrandomised cohort study using a small sample size at a single centre. Therefore, multicenter studies in larger populations are required. Second, we could not completely exclude confounding factors, for example, a delay in treatment initiation, carbapenems being used non-bacterial disease process. Furthermore, we could not exclude selection bias or unpredictable confounding factors because the present study was not a randomised controlled study.
| CON CLUS ION
We demonstrated for the first time that implementing a prospective audit with intervention and feedback without carbapenem restriction facilitated the choice of optimal antimicrobials at an early stage of infection by promoting de-escalation. As a consequence, both the rates of clinical failure and re-infection were remarkably reduced with a concomitant decrease in the incidence of adverse events, including hepatotoxicity, in patients who received carbapenem injection.
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